+39 06 99775399 info@reithera.com
Languages
  • Italiano
  • English
  • Home
  • About
  • R&D
  • CDMO
  • News
    • Grants
    • Press Release
    • Publications
    • Events
  • Contact
  • English
    • Italian
An ideal partner for your biotechnological journey An ideal partner for your biotechnological journey
  • Home
  • About
  • R&D
  • CDMO
  • News
    • Grants
    • Press Release
    • Publications
    • Events
  • Contact
  • English
    • Italian

News

News
0
By ef
In News, Press Release
Posted April 12, 2022

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle- Income Countries

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle- Income Countries Collaboration awarded €3 million [...]

READ MORE
0
By ef
In News
Posted March 24, 2022

ReiThera’s project has been approved, in response to the Lazio Region Public Notice “Digital Diagnostic Voucher”

  With the public notice “Contributions for the support of digitalization processes of companies in the Lazio region – Digital Diagnostic Voucher”, the Lazio Region intends [...]

READ MORE
0
By ef
In News, Publications
Posted January 25, 2022

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Originally published on npj Vaccines volume 6, Article number: 131 (2021). Chiara Agrati, Stefania Capone, Concetta Castilletti, Eleonora Cimini, Giulia Matusali, Silvia Meschi, Eleonora [...]

READ MORE
0
By ef
In News, Publications
Posted January 24, 2022

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Originally published on Sci Transl Med. 2021 Oct 26. doi: 10.1126/scitranslmed. abj1996.

READ MORE
0
By ef
In News, Publications
Posted January 23, 2022

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Originally published on Molecular Therapy Volume 29, Issue 8, 4 August 2021, Pages 2412-2423 Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, [...]

READ MORE
0
By ef
In News, Publications
Posted January 22, 2022

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Originally published on Science. 2021 Jan 29;371(6528):521-526. doi:10.1126/science.aax8819.PMID: 33510029. Capone S, Brown A, Hartnell F, Sorbo MD, Traboni C, Vassilev V, Colloca S, Nicosia A, [...]

READ MORE
0
By ef
In News, Publications
Posted January 21, 2022

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Originally published on PLoS neglected tropical diseases. 2020 Jul 15. 14(7): e0008459. doi: 10.1371/ journal. pntd.0008459. 

READ MORE
0
By ef
In News, Press Release
Posted November 3, 2021

ReiThera Awarded Grant to Develop Next Generation Vaccines

Program funded by the Bill & Melinda Gates Foundation will use ReiThera’s GRAd platform technology to develop next generation vaccines against SARS-CoV-2 emerging variants and HIV ROME, [...]

READ MORE
0
By ef
In News, Press Release
Posted November 2, 2021

Positive Results from ReiThera’s Phase 1 Trial with COVID-19 Vaccine Candidate GRAd-COV2 Published in Science Translational Medicine

ROME, Italy, October 29th, 2021 – ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products [...]

READ MORE
 Sviluppo di Approcci Terapeutici Innovativi per patologie neoplastiche resistenti ai trattamenti (SATIN)
0
By ef
In Grants, News
Posted August 26, 2021

Sviluppo di Approcci Terapeutici Innovativi per patologie neoplastiche resistenti ai trattamenti (SATIN)

    Nel progetto SATIN sono coinvolti numerosi soggetti partner imprese e organismi di ricerca pubblici; il Soggetto Proponente/Aggregatore è Distretto Tecnologico Campania Bioscience [...]

READ MORE
1 2 3 4 5
page 1 of 5
Our privacy

Privacy Policy and Cookie Law

Modello Organizzativo 231

Follow us
  • linkedin
  • facebook
  • instagram
  • twitter

ReiThera srl is a biotech company developing products based on gene delivery technologies for advanced therapies, from early development to final QP release.

© Copyright 2018 | Made with by